Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C21H27N3O7S.ClH |
| Molecular Weight | 501.981 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCOC(=O)OC(C)OC(=O)[C@@H]1N2[C@H](SC1(C)C)[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C2=O
InChI
InChIKey=IWVTXAGTHUECPN-ANBBSHPLSA-N
InChI=1S/C21H27N3O7S.ClH/c1-5-29-20(28)31-11(2)30-19(27)15-21(3,4)32-18-14(17(26)24(15)18)23-16(25)13(22)12-9-7-6-8-10-12;/h6-11,13-15,18H,5,22H2,1-4H3,(H,23,25);1H/t11?,13-,14-,15+,18-;/m1./s1
| Molecular Formula | C21H27N3O7S |
| Molecular Weight | 465.52 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/mtm/bacampicillin.htmlCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/6762528 | http://www.antimicrobe.org/drugpopup/Bacampicillin.pdf
Sources: https://www.drugs.com/mtm/bacampicillin.html
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/6762528 | http://www.antimicrobe.org/drugpopup/Bacampicillin.pdf
Bacampicillin is a penicillin antibiotic. It is a prodrug of ampicillin with improved oral bioavailability. It exerts bactericidal activity via inhibition of bacterial cell wall synthesis by binding one or more of the penicillin binding proteins (PBPs). Spectrobid is used to treat bacterial infections such as tonsillitis, pneumonia (lung infection), bronchitis (inflammation of airway), urinary tract infections, gonorrhea, and infections of the skin. Adverse effects are: anemia, thrombocytopenia, neutropenia, agranulocytosis, seizures, nephrotoxicity, Jarisch-Herxheimer Reaction (fever, chills, sweating, tachycardia, hyperventilation, flushing, and myalgia). Drug interactions: Contraceptives - decreased contraceptive effectiveness; Live Typhoid Vaccine - decreased immunological response to the typhoid vaccine; Probenecid - increased bacampicillin levels.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | SPECTROBID Approved UseBacampicillin is used to treat many different types of infections, such as tonsillitis, pneumonia, bronchitis, urinary tract infections, gonorrhea, and infections of the skin. Launch Date1980 |
|||
| Curative | SPECTROBID Approved UseBacampicillin is used to treat many different types of infections, such as tonsillitis, pneumonia, bronchitis, urinary tract infections, gonorrhea, and infections of the skin. Launch Date1980 |
|||
| Curative | SPECTROBID Approved UseBacampicillin is used to treat many different types of infections, such as tonsillitis, pneumonia, bronchitis, urinary tract infections, gonorrhea, and infections of the skin. Launch Date1980 |
|||
| Curative | SPECTROBID Approved UseBacampicillin is used to treat many different types of infections, such as tonsillitis, pneumonia, bronchitis, urinary tract infections, gonorrhea, and infections of the skin Launch Date1980 |
|||
| Curative | SPECTROBID Approved UseBacampicillin is used to treat many different types of infections, such as tonsillitis, pneumonia, bronchitis, urinary tract infections, gonorrhea, and infections of the skin. Launch Date1980 |
|||
| Curative | SPECTROBID Approved UseBacampicillin is used to treat many different types of infections, such as tonsillitis, pneumonia, bronchitis, urinary tract infections, gonorrhea, and infections of the skin. Launch Date1980 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
13.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/529016 |
808 mg single, oral dose: 808 mg route of administration: Oral experiment type: SINGLE co-administered: |
BACAMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.09 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/529016 |
808 mg single, oral dose: 808 mg route of administration: Oral experiment type: SINGLE co-administered: |
BACAMPICILLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
3200 mg single, oral Highest studied dose |
healthy, 22-41 years Health Status: healthy Age Group: 22-41 years Sex: M+F Sources: |
|
1600 mg 2 times / day multiple, oral Highest studied dose Dose: 1600 mg, 2 times / day Route: oral Route: multiple Dose: 1600 mg, 2 times / day Sources: |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001-11 |
|
| beta-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies. | 1996-07-01 |
|
| Clinical trial of bacampicillin in acute bacterial infections. | 1983 |
Sample Use Guides
Upper respiratory tract infections, Urinary tract infections, skin infections: 400 mg q12h; treat for a minimum of 48-72 hours after the patient becomes asymptomatic.
Severe infections: 800 mg q12h; treat for a minimum of 48-72 hours after the patient
becomes asymptomatic.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10998023
Bacampicillin-treated lymphocyte cultures (200 ug/ml) from the two retested patients with allergic contact dermatitis showed an IFN-gamma production that peaked at 96 h or later. The four retested patients with rhinitis showed no or low IFN-gamma production which peaked at 48 h or 72 h. Two of them responded with IL-4 production.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:10:12 GMT 2025
by
admin
on
Mon Mar 31 18:10:12 GMT 2025
|
| Record UNII |
PM034U953T
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
441398
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
SUB00649MIG
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
C011674
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
PM034U953T
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
DTXSID0045466
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
DBSALT000831
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
37661-08-8
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL1583
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
2969
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
253-580-4
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
100000092774
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
327584
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB32681
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
758228
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
C65246
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | |||
|
m2194
Created by
admin on Mon Mar 31 18:10:12 GMT 2025 , Edited by admin on Mon Mar 31 18:10:12 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |